Just - Evotec Biologics provides contract development and manufacturing organization (CDMO) services for antibody and biologic products using a continuous bioprocessing platform that enhances production efficiency and product quality. This approach addresses the high costs and limited access to affordable biotherapeutics by enabling scalable manufacturing in smaller, modular facilities.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Traditional methods of producing biotherapeutics often involve batch manufacturing, which can be inefficient, costly, and require large facilities. This can limit the accessibility and affordability of these life-saving treatments, hindering global access to high-quality biologics.
Solution
Just - Evotec Biologics is a contract development and manufacturing organization (CDMO) that leverages a continuous bioprocessing platform to provide efficient and cost-effective manufacturing of antibodies, next-generation biologics, and biosimilars. Their integrated, end-to-end continuous manufacturing process is highly intensified, enabling significantly more product to be generated within a smaller footprint compared to traditional batch methods. This optimized bioprocess platform continuously purifies antibodies and recombinant proteins from perfusion cell culture bioreactors, resulting in enhanced product quality. The smaller footprint translates to smaller, more cost-effective, and rapidly constructed manufacturing plants, offering increased flexibility and the capacity to produce up to two metric tons of product annually.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking efficient and cost-effective development and manufacturing solutions for antibody, next-generation biologic, and biosimilar products.
Features
- Integrated end-to-end continuous manufacturing process platform
- Intensified bioprocessing for higher product yields in a smaller footprint
- Continuous purification of antibodies and recombinant proteins from perfusion cell culture bioreactors
- Modular clean room pods (J.PODs) housing highly automated continuous processes
- cGMP biomanufacturing services from early clinical stages to commercial supply
- Cell line development, analytical, and process development services